broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K19687926-001-04-1 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.918946 | 2.417914 | 0.060715 | 0.948541 | 0.021094 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000972 |
BRD-K19796430-001-05-6 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.918995 | -0.673899 | 0.06206 | 0.981745 | 0.003729 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000972 |
BRD-K22064724-001-01-8 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.06809 | 5.336416 | 0.639188 | 0.824339 | 1.605303 | 1.64995 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000972 |
BRD-K22822991-001-02-3 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.84434 | 1.491588 | 0.128126 | 0.906365 | 0.029097 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000972 |
BRD-K23228615-001-02-8 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.297195 | 2.862006 | 0.842825 | 0.853707 | 1.327892 | 1.820085 | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000972 |
BRD-K23984367-001-07-5 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.244905 | 1.691129 | 0.450491 | 0.963318 | 8.892935 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000972 |
BRD-K26026438-001-01-0 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.701863 | 0.76324 | 0.258132 | 0.906212 | 0.535585 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000972 |
BRD-K26657438-001-15-2 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.067059 | 0.154969 | -0.034261 | 1 | 0.000054 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000972 |
BRD-K28822270-001-03-7 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.162137 | 1.194761 | 0.768617 | 0.7221 | 0.426193 | 0.591689 | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000972 |
BRD-K29905972-001-06-3 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.862258 | 0.296417 | 0.026328 | 0.932519 | 0.091556 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000972 |
BRD-K30577245-001-05-0 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.62668 | 5.797472 | 0.375897 | 0.821788 | 0.006078 | null | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000972 |
BRD-K31698212-001-02-9 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.236549 | -0.172786 | 0.015611 | 1 | 0.068629 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000972 |
BRD-K31928526-001-02-1 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.733438 | 5.54347 | 0.257646 | 0.912639 | 0.415641 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000972 |
BRD-K33379087-001-07-5 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.707667 | 0.117237 | -0.006657 | 0.865563 | 0.319473 | null | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000972 |
BRD-K33610132-001-02-9 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.48922 | 1.392598 | 0.328575 | 0.930862 | 3.048413 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000972 |
BRD-K33622447-066-01-9 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.584943 | 5.359281 | 0.562011 | 0.908453 | 1.175957 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000972 |
BRD-K35520305-001-16-9 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.538348 | -0.224659 | -0.146287 | 0.897615 | 0.000181 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000972 |
BRD-K36627727-001-05-4 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.208527 | 2.821706 | 0.031388 | 0.992922 | 15.751164 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000972 |
BRD-K36788280-001-01-2 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.890447 | 0.125911 | -0.000528 | 0.933135 | 0.001985 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000972 |
BRD-K37379014-001-02-0 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.412122 | 0.400805 | 0.160346 | 0.717182 | 0.001557 | 0.119179 | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000972 |
BRD-K38332599-001-01-3 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.50552 | 3.355335 | 0.469525 | 0.782139 | 0.13902 | null | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000972 |
BRD-K38527262-300-01-0 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | -0.075701 | 4.037894 | 0.402017 | 0.956841 | 6.60572 | 6.379053 | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000972 |
BRD-K38852836-001-02-1 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.219122 | 1.699473 | 0.839623 | 0.698047 | 0.058772 | 0.082517 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000972 |
BRD-K39974922-001-04-3 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.951608 | -0.641222 | -0.089674 | 0.97815 | 0.046665 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000972 |
BRD-K41859756-001-06-8 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.201722 | 0.828236 | 0.848237 | 0.614183 | 0.023132 | 0.043161 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000972 |
BRD-K42495768-001-01-7 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.46344 | 1.121114 | 0.387205 | 0.920901 | 2.921593 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000972 |
BRD-K42805893-001-04-9 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.734448 | 0.075598 | 0.026176 | 0.869912 | 0.134259 | null | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000972 |
BRD-K42828737-001-03-3 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.051147 | -0.254102 | -0.017337 | 1 | 5.061543 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000972 |
BRD-K42898655-001-01-8 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.644237 | -0.049617 | -0.022911 | 0.8314 | 0.000589 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000972 |
BRD-K43389675-001-02-1 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.060232 | 8.063944 | 0.896945 | 0.689975 | 0.407006 | 0.41353 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000972 |
BRD-K44227013-001-06-4 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.122279 | 1.177758 | 0.622648 | 0.84109 | 1.935009 | 2.455269 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000972 |
BRD-K44408410-001-17-6 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.616418 | 0.973464 | 0.166185 | 0.874437 | 0.436819 | null | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000972 |
BRD-K44827188-001-06-0 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.96893 | 0.685539 | 0.010868 | 0.983713 | 0.060675 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000972 |
BRD-K46386702-001-02-1 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.029919 | -0.085945 | -0.004169 | 1 | 0.227272 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000972 |
BRD-K49328571-001-15-0 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.263747 | 0.174249 | 0.379649 | 0.550251 | 0.005055 | 0.373478 | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000972 |
BRD-K49350383-001-14-5 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.36386 | 0.306227 | -0.030858 | 1 | 0.005616 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000972 |
BRD-K50010139-001-01-5 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.070722 | 0.030473 | -0.019278 | 1 | 0.000175 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000972 |
BRD-K50168500-001-07-9 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.015075 | 0.191399 | -0.040418 | 1 | 0.000862 | null | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000972 |
BRD-K51313569-001-07-8 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.836753 | 0.192836 | 0.077882 | 0.91769 | 0.071126 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000972 |
BRD-K51791723-003-01-7 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.088712 | 5.780026 | 0.82776 | 0.728548 | 0.555326 | 0.574413 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000972 |
BRD-K51967704-001-03-6 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.362514 | 4.917731 | 0.735241 | 0.843652 | 0.92539 | 1.203215 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000972 |
BRD-K52313696-001-12-3 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.4991 | 1.032318 | 0.204322 | 0.874642 | 0.956633 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000972 |
BRD-K53414658-001-08-2 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.896239 | 1.903278 | 0.146964 | 0.970066 | 0.609833 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000972 |
BRD-K53972329-001-07-0 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.983898 | -0.147415 | -0.059565 | 0.989038 | 16.374458 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000972 |
BRD-K54256913-001-08-7 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.176832 | 0.436875 | 0.451758 | 0.722879 | 0.619879 | 1.68331 | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000972 |
BRD-K54955827-001-02-2 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.084411 | -0.267675 | -0.008052 | 1 | 0.013094 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000972 |
BRD-K54997624-001-06-0 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | -0.109661 | 1.897719 | 0.60505 | 0.958887 | 10.115206 | 9.111602 | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000972 |
BRD-K55187425-236-05-2 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.280029 | 0.973244 | 0.591194 | 0.557759 | 0.025157 | 0.058489 | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000972 |
BRD-K56343971-001-14-8 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.036825 | 0.054896 | -0.00108 | 1 | 1.294112 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000972 |
BRD-K56981171-001-02-8 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.870076 | -0.106545 | -0.002762 | 0.924176 | 1.990062 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000972 |
BRD-K57080016-001-15-9 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.552669 | 0.312308 | 0.195615 | 0.759785 | 0.04452 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000972 |
BRD-K57169635-001-04-5 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.149511 | 5.537232 | 0.779332 | 0.901487 | 3.250619 | 3.46597 | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000972 |
BRD-K58435339-001-03-0 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.05849 | 0.650421 | 0.50804 | 0.756616 | 1.120985 | 1.357286 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000972 |
BRD-K58529924-001-01-5 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.388948 | 4.672846 | 0.484503 | 0.922472 | 3.095204 | 4.270982 | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000972 |
BRD-K58550667-001-08-7 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.153076 | 13.396926 | 0.709242 | 0.827366 | 0.08644 | 0.088831 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000972 |
BRD-K59317601-001-05-5 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.33998 | 1.286589 | 0.648091 | 0.672385 | 0.080913 | 0.196154 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000972 |
BRD-K59369769-001-22-9 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.072619 | -0.287609 | -0.055088 | 1 | 0.491634 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000972 |
BRD-K60866521-001-07-1 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.199761 | 0.51223 | -0.156027 | 1 | 0.087372 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000972 |
BRD-K60997853-001-02-3 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | -0.110403 | 1.516905 | 0.603525 | 0.898788 | 5.041715 | 4.420334 | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000972 |
BRD-K61192372-001-08-9 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.847588 | -1.161925 | 0.145598 | 0.874215 | 2.088382 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000972 |
BRD-K62008436-001-23-9 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.3636 | 0.639424 | 0.254163 | 0.55781 | 0.000583 | 0.004445 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000972 |
BRD-K62196610-001-01-6 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.210317 | 4.222667 | 0.588315 | 0.968531 | 7.151447 | 8.138129 | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000972 |
BRD-K62200014-003-10-5 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.005073 | -0.106677 | -0.008426 | 1 | 0.113951 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000972 |
BRD-K62391742-001-09-7 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.929739 | -0.98122 | 0.017907 | 0.958333 | 0.196112 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000972 |
BRD-K62627508-001-01-5 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.236837 | 1.325969 | 0.856671 | 0.721978 | 0.293444 | 0.476152 | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000972 |
BRD-K63504947-001-14-7 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.07183 | 0.084655 | -0.014461 | 1 | 0.000129 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000972 |
BRD-K63712959-001-01-8 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.909683 | -0.890498 | 0.055792 | 0.964369 | 0.027183 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000972 |
BRD-K64052750-001-22-5 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.006068 | -0.258459 | -0.022795 | 1 | 0.466994 | null | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000972 |
BRD-K64881305-001-03-7 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.619771 | 3.278724 | 0.406918 | 0.675996 | 0.002555 | null | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000972 |
BRD-K66175015-001-12-4 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.007523 | 2.63512 | 0.704151 | 0.913208 | 4.467383 | 4.493075 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000972 |
BRD-K67844266-003-01-9 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.098492 | 0.98381 | 0.827799 | 0.602538 | 0.140053 | 0.175037 | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000972 |
BRD-K69001009-001-02-8 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.005956 | -0.079384 | -0.010718 | 1 | 36.37199 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000972 |
BRD-K69694239-001-02-2 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.203995 | 6.471144 | 0.841189 | 0.775916 | 0.650916 | 0.705852 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000972 |
BRD-K69776681-001-03-8 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.133308 | 1.063863 | 0.673202 | 0.771953 | 0.829343 | 1.10999 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000972 |
BRD-K70301465-001-05-9 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.09841 | 0.010224 | -0.031239 | 1 | 38,660,736,127.40476 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000972 |
BRD-K73838513-003-05-5 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.296289 | -0.77548 | -0.00363 | 1 | 0.000011 | null | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000972 |
BRD-K74514084-003-09-2 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.710217 | 0.125887 | -0.039639 | 0.825992 | 0.002781 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000972 |
BRD-K75009076-001-02-1 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.063341 | 6.784088 | 0.789979 | 0.886607 | 3.088811 | 3.151146 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000972 |
BRD-K76210423-001-01-6 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.992583 | -0.214502 | 0.002956 | 0.995684 | 0.417249 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000972 |
BRD-K76239644-001-02-6 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.728957 | 0.278542 | 0.100673 | 0.846439 | 0.025929 | null | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000972 |
BRD-K76674262-001-03-3 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.151829 | 4.043758 | 0.85546 | 0.62852 | 0.142583 | 0.155933 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000972 |
BRD-K76908866-001-07-6 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.857681 | -4.311848 | 0.182436 | 0.888596 | 1.214763 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000972 |
BRD-K77625799-001-07-7 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.767321 | -0.235754 | 0.017821 | 0.912256 | 0.007441 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000972 |
BRD-K78431006-001-15-1 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.933701 | -0.202895 | -0.058809 | 0.961491 | 0.442475 | null | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000972 |
BRD-K79254416-001-21-8 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.719173 | -0.011366 | -0.030225 | 0.859099 | 0.143836 | null | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000972 |
BRD-K81016934-001-02-0 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.878632 | 0.046901 | -0.03565 | 0.929475 | 0.000071 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000972 |
BRD-K81418486-001-44-2 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | -0.011632 | 0.740547 | 0.534795 | 0.829488 | 3.129335 | 3.033644 | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000972 |
BRD-K81473043-001-19-5 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.03845 | -0.224628 | -0.047306 | 1 | 2.187543 | null | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000972 |
BRD-K82135108-001-04-3 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.233892 | 2.76836 | 0.881714 | 0.505448 | 0.019022 | 0.023889 | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000972 |
BRD-K82746043-001-19-3 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.555054 | 2.860642 | 0.551182 | 0.881649 | 0.756894 | null | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000972 |
BRD-K82818427-001-04-8 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 1.071344 | -0.142013 | -0.051844 | 1 | 0.088531 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000972 |
BRD-K83029223-001-01-3 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.534798 | 3.77984 | 0.586041 | 0.689965 | 0.00097 | null | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000972 |
BRD-K85402309-043-01-9 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.721551 | 0.072562 | -0.087482 | 0.866643 | 0.252724 | null | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000972 |
BRD-K86118762-001-01-8 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.864727 | -1.175462 | -0.235621 | 0.984155 | 0.001467 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000972 |
BRD-K86972824-001-01-4 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.675577 | 0.150637 | -0.004625 | 0.880194 | 3.179465 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000972 |
BRD-K87737963-001-06-0 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.838251 | 0.015061 | -0.017243 | 0.919628 | 0.178351 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000972 |
BRD-K87782578-001-01-4 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.953954 | -0.032333 | -0.044859 | 0.966049 | 6,056,357,015,393.143 | null | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000972 |
BRD-K87909389-003-03-4 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.167556 | 4.611536 | 0.847848 | 0.554806 | 0.055716 | 0.060872 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000972 |
BRD-K88510285-001-17-8 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.118161 | 4.038234 | 0.69733 | 0.677598 | 0.072039 | 0.077012 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000972 |
BRD-K89014967-001-04-3 | ACH-000972 | HEC151_ENDOMETRIUM | MTS010 | 1 | 0.331718 | 0.085771 | -0.104092 | 0.748539 | 30.73391 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000972 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.